MRNA Moderna Inc

$23.72

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

As Moderna approaches its earnings announcement on November 6, the spotlight is on its strategic pivot from pandemic-driven vaccine sales to a broader pipeline of mRNA-based therapies. With an EPS estimate and whisper number both at $0.00, expectations are tempered, reflecting the company's transitional phase. Analysts are keenly observing how Moderna's revenue estimate of $879.55 million aligns with its efforts to diversify beyond COVID-19 vaccines, especially given its substantial market cap of approximately $9.9 billion. This earnings call will be pivotal in assessing Moderna's progress in leveraging its mRNA technology for new therapeutic areas, a move that could redefine its growth trajectory in the coming years.

Updated On 11/21/2025

About Moderna Inc

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.modernatx.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1682852
Address
200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, US
Valuation
Market Cap
$9.56B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
0.88
Performance
EPS
$-9.28
Dividend Yield
—
Profit Margin
-110.00%
ROE
-28.80%
Technicals
50D MA
$31.24
200D MA
$56.42
52W High
$170.47
52W Low
$23.15
Fundamentals
Shares Outstanding
387M
Target Price
$51.14
Beta
2.23

MRNA EPS Estimates vs Actual

● Estimated
● Actual

MRNA News & Sentiment

Nov 20, 2025 • Benzinga SOMEWHAT-BULLISH
What's Going On With Moderna Stock? - Moderna ( NASDAQ:MRNA )
Shares of Moderna, Inc. ( NASDAQ:MRNA ) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. MRNA is lagging behind market performance. See if it is worth your attention here.
Nov 19, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Is State Street SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Nov 17, 2025 • Zacks Commentary SOMEWHAT-BULLISH
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Nov 14, 2025 • Benzinga NEUTRAL
What's Going On With Merck Stock Friday? - Merck & Co ( NYSE:MRK ) , Cidara Therapeutics ( NASDAQ:CDTX )
Merck & Co. Inc. ( NYSE:MRK ) on Friday agreed to acquire Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.
Nov 13, 2025 • GlobeNewswire NEUTRAL
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
WARMINSTER, Pa., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a corporate update.
Nov 10, 2025 • Motley Fool SOMEWHAT-BULLISH
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.
Telemark Asset Management, LLC established a new position in Moderna ( NASDAQ:MRNA ) , acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November 10, 2025, SEC filing.According to a filing with the U.S.
Sentiment Snapshot

Average Sentiment Score:

0.169
50 articles with scored sentiment

Overall Sentiment:

Bullish

MRNA Reported Earnings

Aug 01, 2025
Jun 30, 2025 (Pre market)
0.85 Surprise
  • Reported EPS: $-2.13
  • Estimate: $-2.98
  • Whisper: —
  • Surprise %: 28.5%
May 01, 2025
Mar 31, 2025 (Pre market)
0.51 Surprise
  • Reported EPS: $-2.52
  • Estimate: $-3.03
  • Whisper: —
  • Surprise %: 16.8%
Feb 14, 2025
Dec 31, 2024 (Pre market)
-0.15 Surprise
  • Reported EPS: $-2.91
  • Estimate: $-2.76
  • Whisper: —
  • Surprise %: -5.4%
Nov 07, 2024
Sep 30, 2024 (Pre market)
1.93 Surprise
  • Reported EPS: $0.03
  • Estimate: $-1.90
  • Whisper: —
  • Surprise %: 101.6%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.05 Surprise
  • Reported EPS: $-3.33
  • Estimate: $-3.38
  • Whisper: —
  • Surprise %: 1.5%
May 02, 2024
Mar 31, 2024 (Pre market)
0.51 Surprise
  • Reported EPS: $-3.07
  • Estimate: $-3.58
  • Whisper: —
  • Surprise %: 14.2%
Feb 22, 2024
Dec 31, 2023 (Pre market)
1.52 Surprise
  • Reported EPS: $0.55
  • Estimate: $-0.97
  • Whisper: —
  • Surprise %: 156.7%
Nov 02, 2023
Sep 30, 2023 (Pre market)
-7.6 Surprise
  • Reported EPS: $-9.53
  • Estimate: $-1.93
  • Whisper: —
  • Surprise %: -393.8%
Aug 03, 2023
Jun 30, 2023 (Pre market)
0.42 Surprise
  • Reported EPS: $-3.62
  • Estimate: $-4.04
  • Whisper: —
  • Surprise %: 10.4%

Financials